Does Anthem (Elevance Health) Cover Crestor (Rosuvastatin)?

What Does Anthem's Formulary Say About Crestor?

Anthem (Elevance Health) places brand-name Crestor on Tier 3 (preferred brand) in the majority of its commercial PPO, HMO, and ACA marketplace formularies. Generic rosuvastatin, which has been available since 2016, sits on Tier 1 or Tier 2 on virtually every Anthem plan. That single formulary design decision drives almost every coverage conversation: Anthem will pay for the molecule, but it prefers you receive it as the generic.

Formulary tiers directly control your copay. A Tier 3 copay on a mid-range Anthem commercial plan often runs $45-$60 per 30-day fill, versus $5-$15 for a Tier 1 generic. The practical implication is that most patients who are prescribed brand Crestor specifically can expect either a step-therapy requirement or a higher cost-share until a medical exception is documented.

Anthem's formulary is plan-specific. The exact tier for your coverage appears in the Summary of Benefits and Coverage (SBC) document and in the online drug lookup tool at anthem.com. Because Anthem operates across 14+ states and administers employer-sponsored, individual market, and government-program plans, the tier for Crestor on your specific plan ID may differ from these general patterns. Always confirm with your plan's formulary prior to filling a new prescription.

The FDA-approved labeling for rosuvastatin covers primary hypercholesterolemia (heterozygous familial and non-familial), mixed dyslipidemia, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia (HoFH), and slowing of atherosclerosis progression. Coverage decisions generally track these FDA-labeled indications closely.

Prior Authorization for Crestor on Anthem Plans

Prior authorization (PA) is required for brand-name Crestor on most Anthem commercial and Medicare Advantage plans. The difficulty level is rated moderate by most clinical pharmacy teams, meaning approval is possible with the right documentation but rarely automatic.

Anthem's PA criteria for Crestor typically include at least the following elements:

Clinical diagnosis. The prescriber must document an approved indication: LDL-C elevation consistent with dyslipidemia, a 10-year ASCVD risk score of 7.5% or higher per the ACC/AHA Pooled Cohort Equations, established ASCVD, or a diagnosis of familial hypercholesterolemia.

Step-therapy failure or contraindication. The patient must have tried and failed at least one preferred generic statin (usually atorvastatin or simvastatin at an adequate dose for 90 days), OR the prescriber must document a medical reason that generic rosuvastatin cannot be used. Intolerances, drug interactions, or formulary-related errors typically do not qualify as a brand-versus-generic exception unless a documented adverse reaction exists.

Prescriber attestation. The prescribing physician or NP/PA must complete Anthem's PA request form, attaching chart notes documenting the step-therapy trial, lipid panel results, and risk-factor summary.

PA approvals are generally valid for 12 months and must be renewed annually. The ACC/AHA 2019 Guideline on Primary Prevention of Cardiovascular Disease states: "A clinician-patient risk discussion should precede statin therapy initiation, incorporating patient preferences, safety, and the potential for ASCVD risk reduction." Anthem's PA form mirrors this language, asking prescribers to confirm that shared decision-making has occurred.

Physicians should submit PA requests electronically through Anthem's provider portal (availiti.com) or via CoverMyMeds. Typical turnaround is 3-5 business days for non-urgent requests and 72 hours for urgent situations.

Step Therapy: Which Statins Must You Try First?

Step therapy at Anthem for Crestor generally requires an adequate trial of at least one generic statin before brand Crestor will be authorized. The required "step" is most commonly atorvastatin (generic Lipitor), the highest-volume statin in the United States, or simvastatin.

An "adequate trial" on most Anthem PA criteria means at least 90 days at a therapeutically equivalent dose. The equivalency table used in clinical practice:

• Atorvastatin 10 mg is roughly equivalent to rosuvastatin 5 mg (moderate-intensity statin).
• Atorvastatin 20-40 mg is roughly equivalent to rosuvastatin 10-20 mg (high-intensity statin).
• Atorvastatin 40-80 mg is roughly equivalent to rosuvastatin 20-40 mg (high-intensity statin).

If the patient tried atorvastatin at a high-intensity dose and experienced myalgia confirmed by creatine kinase (CK) elevation greater than 10 times the upper limit of normal, or if a drug interaction (e.g., with certain HIV antiretrovirals) prohibits atorvastatin use, the prescriber can document an exception. Generic rosuvastatin itself does not satisfy a brand-Crestor exception unless the prescriber argues a formulation difference, which Anthem typically does not accept.

The 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk notes that "statin intolerance affects an estimated 5-10% of statin-treated patients" and recommends careful documentation of the specific adverse effect before switching agents. Capturing this documentation up front is the fastest path through Anthem's step-therapy requirement.

HealthRX Step-Therapy Decision Framework for Anthem Crestor PA

Use this sequence when your prescriber submits a PA for brand Crestor:

1. Confirm the clinical indication appears in the FDA label and aligns with Anthem's covered diagnosis list.
2. Identify whether atorvastatin was tried. If yes, document dose, duration (minimum 90 days), and reason for discontinuation with CK or ALT values if applicable.
3. If atorvastatin was not tried, ask whether a clinical reason (allergy, drug interaction, CYP3A4 concern) exists to skip it. Document this explicitly.
4. If generic rosuvastatin was tried and failed, note the specific lot, dose, and adverse event. Anthem rarely grants a brand exception on this basis alone, but it is documented.
5. Attach the most recent lipid panel (within 6 months), 10-year ASCVD risk calculation, and clinical notes confirming shared decision-making.

What Happens If Anthem Denies Crestor Coverage?

Anthem denials for Crestor typically cite one of three reasons: step-therapy criteria not met, insufficient clinical documentation, or the plan's non-coverage of the brand when a generic equivalent exists. Each reason carries a different appeal strategy.

Internal Appeal (Level 1). File within 180 days of the denial notice for commercial plans. Submit a written letter of medical necessity signed by the prescribing provider, updated chart notes, any peer-reviewed evidence supporting the specific clinical need for brand Crestor (not generic rosuvastatin), and objective data such as lipid panels and adverse-event records. The JUPITER trial (NEJM, 2008; N=17,802) demonstrated that rosuvastatin 20 mg reduced major cardiovascular events by 44% (HR 0.56; 95% CI 0.46-0.69; P<0.00001) in patients with elevated hsCRP, supporting aggressive LDL lowering in high-risk patients. [1] Citing this clinical urgency in the appeal letter strengthens the medical necessity argument for any high-potency statin.

Expedited Internal Appeal. Available when waiting 30+ days for standard review would seriously jeopardize the member's health. Anthem must respond within 72 hours. Patients with recent acute coronary syndrome or very high LDL-C (above 190 mg/dL) may qualify.

External Review / State IRO. If Anthem upholds the denial internally, you have the right to request review by an Independent Review Organization (IRO) under state law and the Affordable Care Act. The IRO's decision is binding on Anthem. In most states, external review requests must be filed within 60 days of the final internal denial notice. The ACA external review provision requires insurers to abide by IRO decisions on medical necessity cases.

State Insurance Commissioner Complaint. Filing a complaint with your state's insurance commissioner does not overturn a denial directly, but it creates a regulatory record and sometimes motivates a plan to reverse course. Anthem operates in states including California (through Anthem Blue Cross), New York, Ohio, Indiana, Virginia, and others, each of which has its own insurance department contact.

The 2022 Endocrine Society Clinical Practice Guideline on Lipid Management states that "high-intensity statin therapy is recommended for patients with established ASCVD," which can serve as direct guideline support in an appeal letter when Anthem denies high-dose rosuvastatin for a secondary prevention patient.

Cost Comparison: List Price vs. What You Can Actually Pay

Brand-name Crestor carries a wholesale acquisition cost of roughly $290 per month for a 30-tablet supply of 20 mg. That number shocks most patients. The good news is that most commercially insured patients do not pay list price, and several cost-reduction pathways exist simultaneously.

Generic rosuvastatin. Generic versions from manufacturers including Teva, Apotex, and Sun Pharma cost as little as $4-$15 per month at GoodRx prices at Costco, Walmart, or Kroger pharmacies. The FDA confirmed generic bioequivalence; generic rosuvastatin delivers the same active molecule at the same dose.

AstraZeneca savings card. AstraZeneca offers a Crestor savings card for commercially insured patients. As of mid-2024, eligible patients may pay as little as $3 per 30-day supply through the brand manufacturer's program. This card cannot be used with federal health programs (Medicare, Medicaid, TRICARE). Anthem's own copay accumulator adjustment program may prevent the savings card from counting toward your deductible or out-of-pocket maximum.

Copay accumulator programs. Anthem, like many large insurers, uses copay accumulator adjustment programs that strip manufacturer assistance from the patient's out-of-pocket tracking. This means even if you pay only $3 out of pocket thanks to the AstraZeneca card, those payments may not count toward your deductible. Budget accordingly for the months when the savings card benefit is exhausted.

Patient assistance programs. AstraZeneca's AZ&Me Prescription Savings program provides Crestor at no cost to patients who meet income criteria (generally household income at or below 600% of the federal poverty level) and lack adequate insurance coverage. Applications are at azandme.com.

Patients who are fully denied coverage and do not qualify for the manufacturer program may find that generic rosuvastatin 20 mg or 40 mg, sourced through a discount pharmacy platform, delivers identical LDL-C lowering at a fraction of the cost. Switching from brand Crestor to generic rosuvastatin from the same insurer formulary tier has not been associated with any measurable difference in LDL-C outcomes in the clinical literature. [2]

Clinical Evidence Supporting Rosuvastatin for ASCVD Prevention

The case for rosuvastatin in high-risk patients rests on a strong clinical trial record. JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), published in the New England Journal of Medicine in 2008 (N=17,802), randomized adults with LDL-C below 130 mg/dL but elevated high-sensitivity C-reactive protein (hsCRP above 2.0 mg/L) to rosuvastatin 20 mg daily or placebo. The trial was stopped early at a median follow-up of 1.9 years because rosuvastatin reduced the composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death by 44% (HR 0.56; 95% CI 0.46-0.69; P<0.00001). [1]

The METEOR trial (N=984) showed that rosuvastatin 40 mg significantly slowed the progression of carotid intima-media thickness over 2 years compared to placebo (P<0.001), supporting its role in subclinical atherosclerosis. [3]

The ACC/AHA 2018 Cholesterol Guideline defines high-intensity statin therapy as atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily, with an expected LDL-C reduction of 50% or more. These specific doses appear in Anthem's own clinical PA criteria documents as benchmarks for "adequate statin therapy." [4]

Familial hypercholesterolemia (FH) deserves specific mention. Heterozygous FH affects approximately 1 in 250 people in the United States, producing LDL-C values commonly exceeding 190 mg/dL from birth. In these patients, rosuvastatin 40 mg achieves roughly 55-60% LDL-C reduction, making it one of the two high-intensity statins recommended by the American Heart Association's 2023 Scientific Statement on FH. Anthem's PA criteria for FH patients generally have a separate pathway that may not require step therapy, reflecting guideline recognition that FH-level LDL-C requires immediate high-intensity statin initiation. [5]

Anthem Medicare Advantage and Crestor Coverage

Medicare Advantage (MA) plans administered by Anthem (marketed as Anthem MediBlue, Anthem HealthKeepers Plus, and related products) follow Part D formulary rules set by CMS. Under Part D, rosuvastatin is a protected class drug only insofar as statins are commonly required in formularies, but brand Crestor is not a protected class drug and plans are not required to cover it when a generic equivalent exists.

On most Anthem MA Part D formularies, generic rosuvastatin is covered at a $0-$10 preferred copay. Brand Crestor is either not listed, placed on a non-preferred brand tier with a $47+ copay, or subject to a PA requirement. CMS requires that Part D plans cover at least two drugs per therapeutic category, and generic rosuvastatin satisfies that requirement for the statin class.

Medicare patients who believe brand Crestor is medically necessary can file a formulary exception request, which mirrors the commercial PA process. The prescriber must document why generic rosuvastatin is inadequate. Formulary exceptions under Part D are governed by CMS Medicare Prescription Drug Benefit Manual, Chapter 18. CMS requires a decision within 72 hours (24 hours for expedited requests).

Low-income subsidy (Extra Help / LIS) beneficiaries automatically receive $0-$3.90 copays for generics including rosuvastatin on any Part D plan, making the cost argument for brand Crestor largely moot for this population.

How Providers Can Optimize the PA Submission

Getting a Crestor PA approved through Anthem requires clinical documentation that mirrors the plan's criteria exactly. Vague notes stating "patient needs brand Crestor" rarely succeed.

A high-yield PA letter for Crestor should include: the patient's most recent fasting lipid panel with LDL-C value and date; the calculated 10-year ASCVD risk score (use the ACC ASCVD Risk Estimator at tools.acc.org); documentation of any prior statin trial including drug name, dose, duration, and reason for stopping; clinical indication (HeFH, established ASCVD, primary prevention with high risk); and a direct statement that the generic equivalent is inadequate for a specific documented reason.

If the patient tolerated generic rosuvastatin in the past and is now prescribed brand Crestor for a non-clinical reason (such as patient preference or pill appearance), Anthem will deny the PA. The brand-versus-generic distinction must rest on a clinical rationale, not convenience.

Electronic PA submission through CoverMyMeds reduces turnaround time compared to fax in most Anthem regions. Anthem's real-time PA system, available through the availiti.com provider portal, gives immediate approval or denial for select drug-plan combinations.

For patients with an urgent cardiovascular need, the prescribing team can dispense a 30-day supply of generic rosuvastatin while the PA for brand Crestor is pending, ensuring no therapeutic gap. Anthem allows a one-time emergency fill bypass at retail pharmacies for certain drug classes; confirm with the dispensing pharmacy whether rosuvastatin qualifies under the patient's specific plan.

Documenting the LDL-C goal is equally important. The ACC/AHA 2018 Guideline specifies an LDL-C goal of <70 mg/dL for very high-risk ASCVD patients and <55 mg/dL for patients with multiple high-risk features. [4] Noting the specific LDL-C target and the patient's current value gives the reviewer a clear picture of clinical urgency.